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Introduction
Esophageal variceal hemorrhage is a devastating com-
plication of portal hypertension. It is associated with a
high morbidity and mortality.1 The mechanisms under-
lying rupture of esophageal varices are poorly defined.
It has been demonstrated that the portal pressure is
usually > 10 mmHg in patients who develop esopha-
geal varices and the portal pressure generally exceeds
12 mmHg in patients with rupture of varices. To con-
trol acute variceal bleeding, treatment modalities such
as vasoconstrictors, balloon tamponade, endoscopic
injection sclerotherapy (EIS) and endoscopic variceal
ligation (EVL) may be employed.2,3 Once acute bleed-
ing is successfully controlled, rebleeding may occur in
approximately 2-thirds of patients if further preven-
tive measures are not taken.1 Several factors have been
noted to be associated with the occurrence of variceal
rebleeding; portal pressure, poor liver reserve, sizes of
varices, red color signs on varices, treatment modalities
of acute bleeding, infection and portal vein thrombo-
sis have all been presumed to be related to variceal
rebleeding.4–6 Except for moribund patients, measures
should be taken to reduce variceal rebleeding episodes
to improve patient survival. The time frame of variceal
rebleeding can be divided into very early rebleeding
(within 5 days of acute bleeding), early rebleeding
(within 6 weeks of acute bleeding) and delayed rebleed-
ing. By definition, prevention of variceal rebleeding
starts on day 6.7 Numerous modalities have been devel-
oped to prevent variceal rebleeding. The measures used
to prevent very early rebleeding and delayed rebleed-
ing are quite different. This review will focus on the
methods used for secondary prophylaxis excluding
very early rebleeding. Which method is the most popu-
lar? Which method has the least possibility of induc-
ing complications? What kind of complications may be
encountered in patients who receive preventive therapy?
If initial preventive therapy has failed in a patient, what
should be the second line measure? These questions
are addressed in this comprehensive review.
Surgery
Approximately 3 decades ago, shunting operation
and devascularization procedures were widely adopted
to prevent variceal rebleeding. Undeniably, operative
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measures can generally achieve a rather low incidence of
rebleeding. Shunting operations such as Warren shunt
or Sarfeh’s procedures or the devascularization method
developed by Sugiura and Futagawa all achieved a
rebleeding rate of < 10%.8,9 However, these procedures
are time-consuming and technically difficult operations,
requiring great surgical expertise.8,9 It was presumed
that a selective shunt might have a lower incidence of
hepatic encephalopathy than a nonselective shunt. A
large study from the United States comparing distal
splenorenal shunt (DSS) and portosystemic shunt (PSS)
suggested that 30-day operative mortality was 9% for
DSS patients and 13% for PSS patients, and rebleeding
rate was 18% for the DSS group and 12% for the PSS
group (not significantly different), with encephalopathy
occurring in 51% of the DSS group and in 45% of the
PSS group (not significantly different).10 Child-Pugh
class A patients are good candidates for surgical inter-
vention. Though patients with poor hepatic reserve
treated with shunt operation can still achieve a rather
low variceal rebleeding rate, they may experience high
intraoperative mortality or serious complications. With
the advent of EIS around 1980, surgical modality
gradually yielded to EIS because of the advantages of
the lower risk of complications as well as possibly
improved survival. The other disadvantage of shunting
operation is that it may increase technical difficulty
when patients receive liver transplantation. Nowadays,
surgery is reserved for patients with repeated bouts 
of rebleeding despite repeated endoscopic treatments.
After the development of transjugular intrahepatic por-
tosystemic stent shunt (TIPS), the role of surgery in
rescue for endoscopic and/or medical treatment failure
cases appears to have been replaced by TIPS.
EIS
EIS using quinine as a sclerosant was first introduced
by Crafoord and Frenckner, two Swedish surgeons, in
1939.11 Subsequently, other sclerosants such as sodium
morrhuate, podidocanol, ethanolamine, and sodium
tetradecyl sulfate were more widely used. The mecha-
nisms of EIS are via injection of sclerosants resulting in
tissue necrosis and finally fibrosis, causing obliteration
of varices. The techniques of EIS vary widely among
different clinicians. The optimal dose of sclerosants is
unknown. The treatment can be injected either intra-
variceally or paravariceally. The treatment interval var-
ied between a few days to weeks. Fortunately, EIS
appeared to be uniformly beneficial, regardless of the
variation in techniques.12 In the full-blown era of sur-
gery, EIS was not regarded as a useful tool to prevent
variceal rebleeding and lapsed into obscurity. In 1973,
Johnston and Rodgers reported that EIS could achieve
a rather satisfactory effect to prevent variceal rebleeding
and offer low mortality.13 These results ignited the
enthusiasm for EIS, akin to a renaissance of EIS. Since
then, EIS has been widely employed to prevent variceal
rebleeding, until the advent of EVL.
Four widely-cited controlled studies, the South
African trial, the Los Angeles trial, the Copenhagen
trial and the King’s College trial, were published around
1983–1985.14 Reduced variceal rebleeding with EIS
was shown in 2 studies and improved survival was shown
in only 1 study. Recurrent variceal bleeding was reduced
from 54–82% in the control group to 48–55% after
repeated sessions of EIS. However, a number of local
and systemic complications may be encountered after
EIS.15 These complications encompass ulcer bleeding,
esophageal stricture, fever, pleural effusion, bacteremia,
spontaneous bacterial peritonitis, distant embolism and
distant abscess. It is impossible to predict what kind of
complications may be encountered in patients receiving
EIS. Mortality resulting directly from complications
may be noted in 2% of patients. Meta-analyses of the
trials published between 1982 and 1991, comparing
EIS with “nonactive” treatment, showed that patients
treated with long-term EIS had a significantly lower
rebleeding rate (pooled odds ratio, OR, 0.57; 95%
confidence interval, CI, 0.45–0.71) and better sur-
vival than those who received only nonactive treatment
(pooled OR, 0.72; 95% CI, 0.57–0.90).16,17 During
the same period, EIS was also popular in Taiwan, but
no controlled trial was performed.18,19 Among patients
receiving endoscopic therapy, the variceal rebleeding
rate could only be greatly reduced after variceal oblit-
eration. In Lai et al’s study, a mean of 10 sessions of
EIS was required to achieve variceal obliteration.18
This constitutes another drawback of EIS.
Medical Therapy
In 1981, Lebrec et al found that propranolol could
reduce portal pressure and be used to prevent upper
gastrointestinal hemorrhage related to portal hyperten-
sion.20 The mechanisms of β-blocker action are believed
to be via a reduced cardiac output and a predominant
effect on the unopposed α-adrenergic receptor over
the splanchnic vessels, resulting in reduced blood flow.
Due to the introduction of propranolol in the preven-
tion of variceal rebleeding, a new era began for the treat-
ment of variceal rebleeding. Drug therapy for portal
hypertension has the advantages of being simpler, lower
risk and more economic than endoscopic therapies.
Nonselective β-blockers such as propranolol and nado-
lol are the most widely used drugs in the prevention
of variceal rebleeding. Theoretically, it is better to
detect the hemodynamic response in patients taking
portal hypotensive drugs. The aims are reduction of
the portal pressure to < 12 mmHg or > 20% compared
with baseline levels. However, the measurement of
portal pressure is invasive and not feasible in every
patient. Thus, the dosage of β-blockers is generally
based on the dosage to reduce pulse rate by 25%.
Meta-analyses of the 12 randomized trials published
between 1981 and 1991 showed that patients receiv-
ing β-blockers had a lower incidence of rebleeding
(pooled OR, 0.69) and mortality (pooled OR, 0.78)
compared to patients who did not receive any specific
measure.21 Sheen et al from Taiwan also showed that
propranolol could be used to prevent variceal rebleed-
ing.22 The contraindications for β-blockers include
asthma, bradycardia, atrioventricular block, hypoten-
sion and poorly controlled hyperglycemia. The adverse
effects are usually modest, including bradycardia, chest
tightness, hypotension, dizziness or impotence.
On the other hand, it has been shown that up 
to 1-third of patients may be non-responders to 
β-blockers. The addition of isosorbide mononitrate
(ISMN) has been demonstrated to enhance the effect
of β-blockers in reducing portal pressure through the
decrease of hepatic resistance.23 A controlled study
showed that cirrhotic patients receiving propranolol
and ISMN had a lower variceal rebleeding rate com-
pared to patients who only received propranolol.24
Hence, the combination of β-blockers and ISMN rather
than using β-blockers alone to treat portal hyperten-
sion has become routine clinical practice. However, if
hemodynamic study is feasible, the addition of ISMN
would be unnecessary in patients who are responders
to β-blockers alone.
Comparison of EIS and Medical Therapy
Both β-blockers and EIS were important and popular
modalities in the prevention of variceal rebleeding dur-
ing the 1980s. Studies comparing EIS and β-blockers
were widely performed. A meta-analysis of 9 trials
comparing β-blockers with EIS showed a significant
reduction of rebleeding in favor of EIS (pooled OR,
0.64; 95% CI, 0.48–0.85).25 However, significantly
more complications were encountered in patients who
received EIS,25 while survival was similar between both
therapies. A controlled trial showed that the combina-
tion of nadolol and ISMN was superior to EIS in the
reduction of variceal rebleeding.26 Hence, in the 1990s,
it was recommended that β-blockers, rather than EIS,
be the first choice of treatment to prevent recurrent
variceal bleeding.25
EVL
In 1989, Stiegmann et al first introduced the applica-
tion of EVL to treat esophageal varices.27 In contrast
with the chemical action induced by EIS, EVL works
through mechanical strangulation by rubber bands,
just like its use in the treatment of hemorrhoids. Also,
different from the many technical variations practiced
in EIS, the techniques of EVL appear to be unani-
mously similar. Initially, a single ligator associated with
an overtube was employed to ligate varices. Subse-
quently, the multiband ligator was invented to avoid
the use of an overtube and its associated complications.
No significant differences in efficacy exist between these
ligators. The complications of EVL include esophageal
laceration or perforation (mostly due to trauma of the
overtube), transient dysphagia, retrosternal pain, ulcer
bleeding and bacteremia.
It is well documented that EVL requires about
1–2 sessions fewer than EIS to obliterate esophageal
varices. Between 1992 and 1996, 13 studies, including
2 from Taiwan, comparing EIS and EVL in the pre-
vention of variceal rebleeding were published.28–32 All
these studies demonstrated that EVL was superior to
EIS in terms of reducing rebleeding rates and compli-
cation rates, but only 2 trials showed better survival
with EVL.27,30 A meta-analysis showed a strong bene-
fit for EVL in reducing variceal rebleeding (pooled
OR, 0.46; 95% CI, 0.35–0.60) and similar survival
between patients treated with EIS and those treated
with EVL.16 Therefore, it is recommended that EVL
be the endoscopic treatment of choice for the man-
agement of bleeding esophageal varices.33 The main
disadvantage of EVL is possibly a higher frequency of
recurrent varices.31,34 Fortunately, recurrent varices can
usually be treated with repeated ligation. The meta-
analysis did not show that EVL predisposed patients
to recurrent varices.16
Similar to EIS, the appropriate interval between
EVL sessions has not yet been determined. Most endo-
scopists appear to favor an interval of 1–2 weeks,28–32
whereas I propose that an interval of 3–4 weeks is
more suitable given that unhealed ulcers induced by
ligation are frequently noted within 2 weeks of liga-
tion.5,35 EVL at a longer interval does not result in a
higher rebleeding rate, and in fact, our rebleeding rate
was generally lower than those of other reports.31 A
study from Japan demonstrated that EVL performed
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once every 2 months was better than EVL performed
once every 2 weeks in the overall rates of variceal
recurrence.36 However, EVL performed at intervals of
2 months may be inappropriate in the prevention of
variceal rebleeding. The optimal interval of EVL in the
prevention of variceal rebleeding awaits further study.
Comparison of EVL and Medical 
Therapy
The combination of β-blockers and ISMN being
superior over EIS in reducing variceal rebleeding has
prompted interest in how this combination compares to
EVL.26 Up to now, there has been 4 controlled trials
comparing the combination of nadolol and ISMN with
EVL in the prevention of variceal rebleeding,37–40 
3 reported as full papers and 1 as an abstract (Table 1).
These trials had 3 different results; ours showed that
EVL was superior, another showed that pharmacologic
therapy was superior and the other 2 showed equiva-
lent efficacy for both therapies. Therefore, it is difficult
to draw a conclusion about which therapy is superior.
As mentioned above, 1 of the determining factors of
variceal rebleeding is severity of cirrhosis. The opera-
tors’ expertise in EVL, etiology of cirrhosis, and dosage
of portal hypotensive drugs may also have an impact
on rebleeding rates. Meta-analysis of these 4 studies
showed similar survival between pharmacologic ther-
apy and EVL.41 Thus, either medication with nadolol
plus ISMN or EVL can be used to prevent esophageal
variceal rebleeding.
Combined EIS and EVL
Combination of endoscopic therapies to manage eso-
phageal varices has been a focus of interest for endo-
scopists. In the context of the different mechanisms of
action of EIS and EVL, combining EIS and EVL to
hasten eradication of varices is anticipated. It has been
noted that paraesophageal varices could be obliterated
by EIS but not by EVL.42 The combination of EIS and
EVL is potentially able to reduce the possibility of recur-
rence. The combination of EIS and EVL can be syn-
chronous or metachronous. Between 1996 and 2000,
7 studies were undertaken to investigate the potential
benefits of combined EIS and EVL.43 A meta-analysis of
these studies failed to demonstrate any superiority over
EVL alone in terms of prevention of rebleeding or mor-
tality. Moreover, the combination may be associated
with a higher complication rate of esophageal stricture.
However, EIS plus EVL (the so-called sandwich
method) and EIS with low-dose sclerosants following
repeated EVL has been shown to reduce variceal recur-
rence or even reduce the incidence of variceal rebleed-
ing.44–46 Currently in Taiwan, sclerosants other than
alcohol are not available, thus, it has become difficult
to perform EIS.
Combined EIS and Medical Therapy
The combination of endoscopic therapy and drug ther-
apy for portal hypertension is intriguing. Several reasons
support the addition of drug therapy during endo-
scopic therapy. First, the rebleeding rate remains rather
high after endoscopic therapy, especially before variceal
obliteration is achieved.4 The rebleeding rate is about
30–50% in patients treated with EIS and 20–40% in
patients treated with EVL.16,47 Second, portal hyper-
tensive gastropathy may develop or accentuate after
endoscopic therapy.34,48,49 An increased incidence of
gastric variceal bleeding31,50 after endoscopic therapy
was also noted. Third, portal pressure was noted to be
elevated in approximately 70% of patients in whom
variceal obliteration was achieved by either EIS or
EVL.51,52 Fourth, variceal recurrence is very common
after variceal obliteration achieved by endoscopic ther-
apy.16 It is anticipated that all of these undesirable or
untoward effects of endoscopic therapy can be abol-
ished or alleviated by drug therapy.48,53 A number of
studies were carried out to compare the combination
of propranolol and EIS with propranolol alone or EIS
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Table 1. Controlled studies of endoscopic variceal ligation (EVL) vs. nadolol plus isosorbide mononitrate (N + I) or vs. propranolol plus
isosorbide mononitrate (P + I) to prevent variceal rebleeding
Study Patients (n) Therapy Rebleeding (%) Complication (%) Mortality (%)
Villanueva et al37 72/72 EVL/N + I 44/28* 12/3* 42/32
Lo et al38 61/60 EVL/N + I 20/42* 17/19 25/13
Patch et al39 51/51 EVL/P + I 54/44 14/20 22/32
Romero et al40 57/52 EVL +EIS/N + I 40/37 49/46 19/20
*Significant difference. EIS = endoscopic injection sclerotherapy.
alone.54 Unfortunately, most of the studies did not
show any additional benefit of the combination of EIS
and propranolol over single therapy. The variceal re-
bleeding rates and complications were similar between
the treatments in these studies. It is very probable
that each of these studies had insufficient sample size
to show the benefit of the EIS and propranolol com-
bination. Meta-analysis of the 10 studies between
1986 and 1992 suggested that the combined treat-
ment with EIS and propranolol was significantly bet-
ter than EIS alone in preventing rebleeding (pooled
OR, 0.65; 95% CI, 0.46–0.92), but there was similar
survival with both modalities.54 Interpretation with
caution was warned over the results of the meta-
analysis because of qualitative heterogeneity.16
Combined EVL and Medical Therapy
Contrary to the enthusiasm about EIS plus β-blockers,
the use of EVL and β-blockers in the prevention of
variceal rebleeding is rarely studied. In view of the
superiority of EVL over EIS and nadolol over propra-
nolol, we compared EVL combined with nadolol and
sucralfate to EVL alone in the prevention of variceal
rebleeding.54 The superiority of nadolol over propra-
nolol includes longer half-life and renal metabolism.
The use of sucralfate was to reduce ulcer bleeding pro-
voked by EVL. After a median follow-up of 21 months,
our study showed that the combination of nadolol,
sucralfate and EVL was superior to EVL alone in terms
of variceal rebleeding rates (12% vs. 29%) and variceal
recurrence (26% vs. 50%). We presumed that the bene-
fits of combination therapy were primarily from nadolol
rather than sucralfate, since the incidence of ulcer bleed-
ing during the course of EVL was appreciably low. A
similar study by de la Pena et al also suggested that
the combination of EVL and β-blockers was superior
to EVL alone in reducing variceal rebleeding as well
as in the prevention of variceal recurrence (Table 2).55
However, their patients who were treated with EVL
plus nadolol had a higher frequency of complications,
mostly due to the use of β-blockers.
On the other hand, it is still unknown as to whether
or not EVL enhances the efficacy of β-blockers plus
ISMN in the prevention of recurrent variceal bleed-
ing. We have performed such a study and the results
demonstrated that combined EVL with drug therapy
had a variceal rebleeding rate of 28%, which was mar-
ginally significantly lower than the 48% achieved in
patients treated with drug therapy only (p = 0.05).56
A similar study from Spain with short-term follow-up
showed that the addition of EVL to pharmacologic
therapy reduced the frequency of variceal rebleeding
but resulted in a higher frequency of severe compli-
cations that required hospitalization.57 Thus, for patients
who receive nadolol plus ISMN to prevent variceal
rebleeding, the addition of EVL may further reduce
rebleeding rate but perhaps at the price of more 
complications.
Based on these studies, experts specializing in por-
tal hypertension have had different opinions. Garcia-
Tsao58 and Bosch and Garcia-Pahan59 from Europe
suggested that patients with a history of variceal bleed-
ing could receive either β-blocker or EVL to prevent
rebleeding, whereas the combination of EVL and
nadolol could be reserved for patients in whom EVL or
β-blocker alone has failed. On the other hand, Boyer
from the United States suggested that β-blockers
should be combined with EVL as the treatment of
choice to prevent recurrent variceal hemorrhage.60
β-blockers should be employed during the course of
EVL as well as after variceal obliteration for preventing
variceal recurrence.
TIPS
TIPS has been developed for more than 20 years to
treat portal hypertension. In the past decade, TIPS
was widely applied to prevent gastroesophageal variceal
rebleeding in the West, but the use of TIPS in Taiwan
is very limited.61 This may be ascribed to technical
difficulty in the context of the predominantly post-
necrotic cirrhosis in our country. A meta-analysis of
11 controlled studies comparing TIPS with endoscopic
therapy showed that TIPS achieved a mean variceal
rebleeding rate of 19% compared with 46% achieved by
endoscopic therapy. However, the incidence of hepatic
encephalopathy was 2-fold in patients treated with
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Table 2. Controlled studies of endoscopic variceal ligation (EVL) vs. EVL plus nadolol (EVL + N) to prevent variceal rebleeding
Study Patients (n) Therapy Rebleeding (%) Complication (%) Mortality (%)
Lo et al54 62/60 EVL/EVL + N 29/12* 8/11 32/17
de la Pena et al55 37/43 EVL/EVL + N 38/14* 3/33* 11/11
*Significant difference.
TIPS compared to patients treated with endoscopic
therapy. The survival was similar between the 2 modes
of therapy.62 Moreover, the placement of TIPS requires
frequent interventions to maintain TIPS patency. A
coated stent has been developed to reduce stent occlu-
sion.63 Whether or not TIPS using a coated stent could
have a lower incidence of hepatic encephalopathy and
improved survival awaits further study. Currently, TIPS
is reserved as a rescue therapy for pharmacologic or
endoscopic therapy failure in the prevention of gas-
troesophageal variceal rebleeding and as a bridge to
liver transplantation.64
Summary
There are several methods that a clinician may choose
from for the prevention of variceal rebleeding. Either
nadolol (alone or combined with ISMN), EVL or a
combination of nadolol and EVL (or plus sucralfate)
can be employed as first-line treatment. To avoid com-
plications and to avoid the discomfort induced by
endoscopic therapy, a combination of nadolol and
ISMN can be the first choice. If rebleeding occurs, then
EVL can be tried. If patients are tolerant, repeated EVL
until variceal obliteration can be performed. If rebleed-
ing continues to occur after taking preventive measures,
EVL together with nadolol becomes the treatment of
choice. For patients who have contraindications or
who are intolerant to β-blockers, EVL is the only
choice. A combined approach with EVL and nadolol
can be used as first-line treatment or reserved until
pharmacologic or endoscopic therapy failure. Shunt
operation and TIPS are recommended to be reserved
for esophageal varices that are difficult to manage by
medical modalities. If patients belong to Child-Pugh
class C with repeated variceal bleeding, they should be
put on the waiting list for liver transplantation. The algo-
rithm for prevention of esophageal variceal hemorrhage
is shown in Figure 1. For patients with variceal rebleed-
ing under control, regular screening for occurrence of
hepatocellular carcinoma is advised.65
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